Risk increases significantly in individuals with copper metabolism disorders (Wilsons Disease)
The 2026 patent expiry has made these life-changing GLP-1 medications affordable
Russo FB, Freitas BC, Pignatari GC, Fernandes IR, Sebat J, Muotri AR, Beltro-Braga PCB (2018) Modeling the interplay between neurons and astrocytes in autism using human induced pluripotent stem cells
In addition, few studies currently support the use of GLP-1RAs in patients with HFrEF
Why This Matters for Providers For clinicians in integrative, functional, and regenerative medicine, the update may mark the beginning of a more accessible environment for peptide-based therapies